<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390624</url>
  </required_header>
  <id_info>
    <org_study_id>RMBMT-123</org_study_id>
    <nct_id>NCT00390624</nct_id>
  </id_info>
  <brief_title>Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol</brief_title>
  <official_title>Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rocky Mountain Cancer Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rocky Mountain Cancer Centers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to combine Urodilatin (ANP analogue), which will increase
      glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow
      and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant
      patients in a phase II study comparing results with historical controls.

      We hypothesize that the incidence of renal dysfunction, ARF and thus mortality in allogeneic
      bone marrow transplantation can be significantly reduced by the use of protective agents
      Urodilatin and mannitol. We feel that this combination is best administered prior to and
      during the first two weeks of treatment when patients encounter immunosuppressive agents and
      the onset of early transplantation complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function will be assessed for first 30 days after transplantation for the primary endpoint.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary endpoints will be a comparison of the grades of renal dysfunction, incidence of ARF requiring dialysis, and overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient will be followed at 3 month intervals for the first year and then yearly for life.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Dysfunction</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Mortality</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MANNITOL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  Presence of malignancy or hematological disease whose treatment will be allogeneic
             stem cell transplant and high-dose conditioning therapy.

          -  Adequate baseline evaluation: adequate renal function (creatinine clearance &gt; 60
             ml/min); Adequate hepatic function (SGOT, SGPT, bilirubin and alkaline phosphatase &lt;
             1.5 times normal); adequate cardiac function (MUGA showing a left ventricular ejection
             at rest &gt; 45%); adequate pulmonary function (DCLO &gt; 60%).

        Exclusion Criteria:

          -  Known hypersensitivity to ANP or mannitol

          -  Congestive heart failure

          -  Previous bone marrow transplant

          -  BP less than 90 mm systolic or less than 60 mm Hg diastolic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chirag R Parikh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine (Nephrology)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989 Mar;13(3):210-6.</citation>
    <PMID>2645771</PMID>
  </reference>
  <reference>
    <citation>Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Figuera A, Motellón JL, Paraiso V, Traver JA, Fernandez-Rañada JM. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol. 1995;15(6):473-9.</citation>
    <PMID>8546168</PMID>
  </reference>
  <reference>
    <citation>Létourneau I, Dorval M, Bélanger R, Légaré M, Fortier L, Leblanc M. Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron. 2002 Apr;90(4):408-12.</citation>
    <PMID>11961399</PMID>
  </reference>
  <reference>
    <citation>Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int. 1996 Sep;50(3):1026-31.</citation>
    <PMID>8872980</PMID>
  </reference>
  <reference>
    <citation>Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, Slat-Vasquez V, Shpall EJ, Jones RB, Bearman SI, Schrier RW. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002 Aug;62(2):566-73.</citation>
    <PMID>12110019</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <last_update_submitted>May 30, 2008</last_update_submitted>
  <last_update_submitted_qc>May 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <keyword>Urodilatin</keyword>
  <keyword>Mannitol</keyword>
  <keyword>Acute Kidney Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Ularitide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

